VEGFA and diabetic retinopathy: The rate and nature of adverse events, such as macular atrophy, pigment clumping or epiretinal membrane, in our study population was relatively low and about the same as in other diseases treated with intravitreal anti‐VEGF such as diabetic retinopathy or age‐related macular degeneration.